Nothing Special   »   [go: up one dir, main page]

ES2174538T3 - Procedimiento para la obtencion de substancias exentas de disolventes, no cristalinas, biologicamente activas. - Google Patents

Procedimiento para la obtencion de substancias exentas de disolventes, no cristalinas, biologicamente activas.

Info

Publication number
ES2174538T3
ES2174538T3 ES98965661T ES98965661T ES2174538T3 ES 2174538 T3 ES2174538 T3 ES 2174538T3 ES 98965661 T ES98965661 T ES 98965661T ES 98965661 T ES98965661 T ES 98965661T ES 2174538 T3 ES2174538 T3 ES 2174538T3
Authority
ES
Spain
Prior art keywords
crystallin
solvents
procedure
biologically active
obtaining substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98965661T
Other languages
English (en)
Inventor
Jorg Breitenbach
Ulrich Reinhold
Jurgen Zeidler
Jorg Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Application granted granted Critical
Publication of ES2174538T3 publication Critical patent/ES2174538T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento para la obtención de substancias exentas de disolvente, no cristalinas, biológicamente activas, a partir de las correspondientes substancias cristalinas biológicamente activas en una extrusora, caracterizado porque se funde los cristales de substancia que contienen disolvente en la extrusora bajo vacío, y en ausencia de substancias auxiliares, aplicándose un vacío en una zona de la extrusora.
ES98965661T 1997-11-28 1998-11-09 Procedimiento para la obtencion de substancias exentas de disolventes, no cristalinas, biologicamente activas. Expired - Lifetime ES2174538T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19752895 1997-11-28

Publications (1)

Publication Number Publication Date
ES2174538T3 true ES2174538T3 (es) 2002-11-01

Family

ID=7850166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98965661T Expired - Lifetime ES2174538T3 (es) 1997-11-28 1998-11-09 Procedimiento para la obtencion de substancias exentas de disolventes, no cristalinas, biologicamente activas.

Country Status (11)

Country Link
US (1) US6547997B1 (es)
EP (1) EP1033975B1 (es)
JP (1) JP2001524503A (es)
CN (1) CN1150891C (es)
AT (1) ATE214595T1 (es)
CA (1) CA2310847C (es)
DE (1) DE59803468D1 (es)
DK (1) DK1033975T3 (es)
ES (1) ES2174538T3 (es)
PT (1) PT1033975E (es)
WO (1) WO1999027891A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
WO2009085828A2 (en) * 2007-12-20 2009-07-09 Mutual Pharmaceutical Company, Inc. Quinine sulfate polymorphs, processes of preparing, compositions and uses thereof
JP5774853B2 (ja) * 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
ES2560210T3 (es) 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
CA2839126A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CN104394851B (zh) 2012-04-18 2017-12-01 格吕伦塔尔有限公司 抗篡改和抗剂量‑倾泻药物剂型
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
GB201801415D0 (en) * 2018-01-29 2018-03-14 Univ Limerick Method and apparatus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310676A1 (de) 1983-03-24 1984-09-27 Basf Ag, 6700 Ludwigshafen Verfahren und vorrichtung zum entfernen von fluechtigen anteilen aus polymerenschmelzen oder paste
EP0665009B1 (en) * 1992-10-14 2000-02-16 Nippon Shinyaku Company, Limited Crystalline condition dislocating method
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5466865A (en) * 1993-07-02 1995-11-14 Ibah, Inc. Neomorphic ibuprofen and methods of using same
CN1073563C (zh) * 1994-04-11 2001-10-24 中外制药株式会社 4,6－二叔丁基－2,3－二氢苯并噻吩衍生物
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
NZ322907A (en) 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
DE19624607A1 (de) * 1996-06-20 1998-01-02 Basf Ag Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen
DE19801073A1 (de) * 1998-01-14 1999-07-15 Bayer Ag Mischvorrichtung

Also Published As

Publication number Publication date
CN1280491A (zh) 2001-01-17
EP1033975B1 (de) 2002-03-20
CA2310847A1 (en) 1999-06-10
EP1033975A2 (de) 2000-09-13
US6547997B1 (en) 2003-04-15
WO1999027891A2 (de) 1999-06-10
PT1033975E (pt) 2002-07-31
ATE214595T1 (de) 2002-04-15
JP2001524503A (ja) 2001-12-04
WO1999027891A3 (de) 1999-08-12
CN1150891C (zh) 2004-05-26
DE59803468D1 (de) 2002-04-25
CA2310847C (en) 2007-03-13
DK1033975T3 (da) 2002-05-27

Similar Documents

Publication Publication Date Title
ES2174538T3 (es) Procedimiento para la obtencion de substancias exentas de disolventes, no cristalinas, biologicamente activas.
BG103214A (en) Solid foam-forming active substance containing preparation
ATE296642T1 (de) Reverse-phase zusamensetzung zur bindegewebsreparatur
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
HRP20010277B1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
AR016981A2 (es) Polipeptidos sinteticos
FI970934A (fi) Implantoitava valukappale vaikuttavien aineiden annostelemiseksi kasveihin
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
ZA985471B (en) Absorbent structure comprising a highly absorbent polymer and an absorbent article comprising the absorbent structure
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
BR9708408A (pt) Composições e métodos para peliculas reticuladas de modo seletivo e artigos aperfeiçoados de peliculas resultantes das mesmas
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
EA200000112A1 (ru) Новая композиция
RU96121980A (ru) Биопрепарат фитоспорин для защиты растений от болезней
ES2160893T3 (es) Procedimiento y compuestos intermedios para la preparacion de compuestos de fluoroolefinas plaguicidas.
AU4136897A (en) 2,3-dihydrobenzofuran derivative and hepatopathy remedy comprising the same as active ingredient
ITMI940802A0 (it) Procedimento per la preparazione di derivati di 5.6 diidrossi-2-ammino-1,2,3,4- tetraidronaftalene
ES2191147T3 (es) Composiciones gelificadas basadas en barros termales.
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
ES1035932Y (es) Adimento para implantes perfeccionado.
ES2051916T3 (es) Procedimiento para la obtencion de formiltrimetilbiciclo(2.2.2)oct-7-enos isomeros.
ES1031100Y (es) Protesis para femur, perfeccionada.
ES1021574Y (es) Disposicion de cierre y ajuste para calzado deportivo, perfeccionado.
ES1029989Y (es) Camara perfeccionada para la esterilizacion de alimentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1033975

Country of ref document: ES